机器人辅助微创食管切除术与微创食管切除术的比较:来自一家大容量单中心的倾向匹配研究
该研究在一家大容量中心7年期间,比较机器人辅助微创食管切除术(RAMIE)与微创食管切除术(MIE)治疗食管癌的短期和长期结局。经1:3倾向匹配后,RAMIE组65例、MIE组181例,两组总生存和无病生存无差异,主要并发症无显著差异,但RAMIE组中位淋巴结清扫数更高(32枚 vs 29枚,P=0.02)。
要点
- RAMIE与MIE的总生存(P=0.69)和无病生存(P=0.70)无差异。
- 两组主要并发症如肺炎、乳糜胸、吻合口漏等无显著差异。
- RAMIE组中位淋巴结清扫数高于MIE组(32枚 vs 29枚,P=0.02)。
核心结论
- 机器人辅助微创食管切除术可能改善食管癌患者的淋巴结清扫。
- 微创食管切除术与机器人辅助微创食管切除术在死亡率、并发症和围手术期结局方面相似。
- 需要进一步的前瞻性研究来探究改善的淋巴结切除是否可转化为改善的肿瘤学结局。
研究设计与样本
- 从前瞻性维护的数据库中识别7年期间接受机器人辅助微创食管切除术或标准微创食管切除术的患者。
- 纳入标准为I至III期疾病、手术已过学习曲线、无硬皮病或肝硬化证据。
- 对多个临床协变量进行1:3倾向匹配(机器人辅助微创食管切除术:微创食管切除术)以确定最终研究队列。
- 最终队列共246例,其中机器人辅助微创食管切除术65例、微创食管切除术181例。
主要发现
- 总生存无差异(P=0.69),无病生存无差异(P=0.70)。
- 主要并发症发生率无显著差异:肺炎(17% vs 17%,P=0.34)、乳糜胸(8% vs 9%,P=0.95)、喉返神经损伤(0% vs 1.5%,P=1)、吻合口漏(5% vs 4%,P=0.49)、术中并发症(9% vs 8%,P=0.73)、完全切除率(99% vs 96%,P=0.68)。
- 两组院内死亡(P=0.89)、30天死亡(P=0.66)和90天死亡(P=0.73)无差异。
- 机器人辅助微创食管切除术组中位淋巴结清扫数高于微创食管切除术组(32 vs 29,P=0.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步的前瞻性研究来探究改善的淋巴结切除是否可转化为改善的肿瘤学结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Robotic-assisted minimally invasive esophagectomy accounts for a growing proportion of esophagectomies, potentially due to improved technical capabilities simplifying the challenging aspects of standard minimally invasive esophagectomy. However, there is limited evidence directly comparing both operations. The objective is to evaluate the short-term and long-term outcomes of robotic-assisted minimally invasive esophagectomy in comparison with the minimally invasive esophagectomy approach for patients with esophageal cancer over a 7-year period at a high-volume center. The primary end points of this study were overall survival and disease-free survival. Secondary end points included operation-specific morbidity, lymph node yield, readmission status, and in-hospital, 30-day, and 90-day mortality. METHODS: Patients who underwent robotic-assisted minimally invasive esophagectomy or standard minimally invasive esophagectomy over a 7-year period were identified from a prospectively maintained database. Inclusion criteria were patients with stage I to III disease, operations performed past the learning curve, and no evidence of scleroderma or cirrhosis. A 1:3 propensity match (robotic-assisted minimally invasive esophagectomy:minimally invasive esophagectomy) for multiple clinical covariates was performed to identify the final study cohort. Perioperative outcomes were compared between the 2 operations. RESULTS: A total of 734 patients undergoing minimally invasive esophagectomy (n = 630) or robotic-assisted minimally invasive esophagectomy (n = 104) for esophageal cancer were identified. After exclusions and matching, a total cohort of 246 patients undergoing robotic-assisted minimally invasive esophagectomy (n = 65) or minimally invasive esophagectomy (n = 181) were identified. There was no difference in overall survival (P = .69) or disease-free survival (P = .70). There were no significant differences in rates of major morbidity: pneumonia (17% vs 17%, P = .34), chylothorax (8% vs 9%, P = .95), recurrent laryngeal nerve injury (0% vs 1.5%, P = 1), anastomotic leak (5% vs 4%, P = .49), intraoperative complications (9% vs 8%, P = .73), or complete resection rates (99% vs 96%, P = .68). There was no difference in in-hospital (P = .89), 30-day (P = .66) or 90-day mortality (P = .73) between both cohorts. The robotic-assisted minimally invasive esophagectomy cohort yielded a higher median lymph node harvest in comparison with the minimally invasive esophagectomy cohort (32 vs 29, P = .02). CONCLUSIONS: Robotic-assisted minimally invasive esophagectomy may improve lymphadenectomy in patients undergoing esophagectomy for cancer. Minimally invasive esophagectomy and robotic-assisted minimally invasive esophagectomy are otherwise associated with similar mortality, morbidity, and perioperative outcomes. Further prospective study is required to investigate whether improved lymph node resection may translate to improved oncologic outcomes.
引用
- Ekeke CN, Kuiper GM, Luketich JD, et al. Comparison of robotic-assisted minimally invasive esophagectomy versus minimally invasive esophagectomy: A propensity-matched study from a single high-volume institution. J Thorac Cardiovasc Surg. 2022. PMID: 36732144. doi:10.1016/j.jtcvs.2022.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。